How Long Does Cotinine Stay in Your System? What the Pharmacokinetic Literature Reports

What cotinine is, and why a peptide site covers it

Cotinine is not a peptide. It is a small-molecule alkaloid — the major proximate metabolite of nicotine — and it appears in this guide series because it is one of the most frequently asked-about "how long does it stay in your system" compounds, and because the pharmacokinetic (PK) vocabulary used to answer that question (half-life, clearance, matrix, detection window, metabolic phenotype) is the same vocabulary used across the rest of this library. Where this page describes cotinine specifically, it cites cotinine or nicotine literature directly. Where it describes a general PK principle that applies to many compounds, it says so explicitly and does not dress the principle up as a cotinine-specific finding.

A 2012 review in Frontiers in Pharmacology examined cotinine's pharmacology beyond its conventional role as a biomarker of tobacco consumption (PMID 23087643), which is a useful framing: cotinine is measured because it is convenient and long-lived relative to nicotine, not because it is inert.

How cotinine is formed and cleared

Cotinine is produced when nicotine is metabolised, and the hepatic enzyme CYP2A6 sits at the centre of both that conversion and cotinine's onward metabolism. Researchers evaluating a weighted genetic risk score reported on its ability to predict biomarkers of CYP2A6 activity (PMID 30815984), which is the mechanistic reason two people with identical exposure can show different cotinine levels at the same time point.

Because cotinine is downstream of nicotine, its concentration curve is flatter and longer than nicotine's. General pharmacokinetic principle — not a cotinine-specific measurement: a metabolite that is formed more slowly than it is eliminated will show "formation-rate-limited" kinetics, and a metabolite eliminated more slowly than it is formed will linger well past the parent compound. Cotinine is conventionally treated as the latter, which is exactly why exposure studies sample it rather than nicotine. The verified studies summarised on this page did not supply a single consensus half-life figure, so no number is asserted here; readers looking for a specific value should note that published half-life estimates vary with matrix, assay, population and exposure pattern.

What the human-facing literature has modelled

The most directly relevant human work in this citation set is a physiologically based pharmacokinetic (PBPK) modelling study that addressed nicotine and cotinine clearance in pregnant women (PMID 34354586). PBPK modelling matters for the "how long" question because it builds clearance from organ blood flows, enzyme abundance and protein binding rather than from a single averaged curve — meaning it can express how a physiological state, such as pregnancy, shifts clearance rather than simply reporting one population number. The study addressed a state in which hepatic enzyme activity is known to change; it did not generalise to other populations.

Sampling method also shapes the answer. One report examined cotinine concentration in saliva in relation to oral hygiene procedures (PMID 25799856), which is a reminder that a saliva reading is a measurement of a compartment, not a direct readout of systemic exposure, and that pre-sampling behaviour can move the number.

Matrices and what each one indexes

Animal pharmacokinetic studies

Two animal studies in this set bear directly on cotinine kinetics. Researchers developed an LC-MS/MS method and used it for in vivo quantification and pharmacokinetic study of cotinine in mice after smoke exposure (PMID 31756277). Separately, a 2024 study in Nicotine & Tobacco Research reported a behavioural and pharmacokinetic assessment of nicotine e-cigarette inhalation in female rats (PMID 38092656), pairing exposure with measured pharmacokinetics rather than assuming them.

The standing caveat applies: rodents metabolise nicotine and cotinine on a different timescale from humans, so animal clearance data establish mechanism and method, not human detection windows. Neither study was designed to tell an individual how long a reading will persist.

Detectability and drug-test relevance, stated plainly

This is the point where general internet writing tends to blur two different things, so it is worth separating them.

• Standard workplace drug panels do not test for cotinine. The conventional five-panel and expanded panels target amphetamines, cannabinoids, cocaine metabolites, opiates, phencyclidine and, in extended versions, benzodiazepines, barbiturates, methadone and similar drug classes. Nicotine and cotinine are not part of those panels.
• Cotinine testing is a separate, purpose-ordered test. It is used where tobacco or nicotine exposure status is itself the question — for example in life- and health-insurance underwriting, some pre-transplant assessments, occupational tobacco-free policies, and research studies that need objective verification of exposure or abstinence.
• Cut-offs, not chemistry alone, define the "window." A laboratory reporting threshold determines whether a declining concentration is called positive or negative. Two labs applying different cut-offs to the same sample can produce different answers, which is why no universal number of days applies.
• Secondhand exposure registers. Cotinine assays are sensitive enough that environmental exposure can produce measurable values, which is precisely why it is used to audit exposure-reduction efforts — a 2021 review in Academic Pediatrics asked whether tobacco smoke exposure reduction strategies work (PMID 32097784).

Clinical trials in this area depend on that same biomarker logic: a pivotal multicentre double-blind randomised controlled trial reported on repetitive transcranial magnetic stimulation for smoking cessation (PMID 34505368), and cessation endpoints in trials of this kind are conventionally verified against objective measures rather than self-report alone.

Factors that change how long cotinine persists

Metabolic phenotype and genetics

CYP2A6 activity varies widely between individuals and between ancestry groups. The study evaluating a weighted genetic risk score examined how well genotype predicted biomarkers of CYP2A6 activity (PMID 30815984); slower metabolisers, in general PK terms, hold a metabolite longer than faster ones at equivalent exposure.

Physiological state

Pregnancy is the state explicitly modelled here, in the PBPK analysis of nicotine and cotinine clearance in pregnant women (PMID 34354586). General principle: renal function, hepatic blood flow, body composition and age also enter clearance equations for small molecules, though those specific modifiers were not the subject of the cotinine papers cited on this page.

Product and exposure route

Not all nicotine exposure delivers identical downstream chemistry. A 2015 hypothesis paper in Medical Hypotheses proposed that nicotyrine, a nicotine-related constituent associated with electronic cigarettes, could bear on nicotine's metabolic handling (PMID 26100465); the authors framed it as a hypothesis requiring testing, not as an established kinetic parameter. Route and device also shape the concentration curve, as the rat e-cigarette inhalation work illustrates by measuring pharmacokinetics alongside behaviour (PMID 38092656).

Co-administered drugs

Interaction studies exist for the parent compound: a 2000 report in Clinical Pharmacology and Therapeutics investigated nicotine–mecamylamine interactions (PMID 10945316). General principle: any agent that induces or inhibits the enzymes handling a compound can move its clearance, and cotinine's dependence on CYP2A6 makes it theoretically susceptible to that kind of shift.

Sampling and assay

Matrix choice, timing relative to last exposure, analytical method and reporting threshold all move the measured number. The salivary cotinine report examined concentrations in relation to oral hygiene procedures (PMID 25799856), and the mouse work relied on a validated LC-MS/MS method for quantification (PMID 31756277).

Safety and biological signals in the cited literature: What Studies Report

This page is about persistence, not toxicology, but the cited set includes exposure-outcome work that readers may encounter alongside it. A 2022 review in Comprehensive Physiology covered developmental effects of electronic cigarette use (PMID 35578965). A 2023 preprint reported that tobacco-derived and tobacco-free nicotine caused differential inflammatory cell influx and MMP9 responses in mouse lung (PMID 38077054); as a preprint, it had not completed peer review at posting. The 2012 Frontiers in Pharmacology review argued that cotinine itself has pharmacological properties beyond its biomarker role (PMID 23087643), meaning a persisting cotinine concentration is not automatically inert background.

What this literature does not settle

1. A single number of days. None of the verified studies cited here published a universal human detection window applicable across matrices and cut-offs.
2. Individual prediction. Genetic-score work described prediction of biomarkers of CYP2A6 activity at group level (PMID 30815984), not per-person clearance forecasting.
3. Cross-species transfer. Mouse and rat kinetics (PMID 31756277, PMID 38092656) do not convert directly into human timelines.
4. Anything about accelerating clearance. No study in this set evaluated a method for shortening how long cotinine remains measurable, and this page describes none.

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified clinician about any health question, test result or medication.

Related reading

• Cotinine: compound overview
• How long do peptides stay in your system?

References

• Physiologically Based Pharmacokinetic Modelling for Nicotine and Cotinine Clearance in Pregnant Women (Frontiers in Pharmacology, 2021)
• In vivo quantification and pharmacokinetic studies of cotinine in mice after smoke exposure by LC-MS/MS (Biomedical Chromatography, 2020)
• Behavioral and Pharmacokinetic Assessment of Nicotine e-Cigarette Inhalation in Female Rats (Nicotine & Tobacco Research, 2024)
• Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity (Addiction Biology, 2020)
• Cotinine concentration in the saliva in relation to oral hygiene procedures (Przeglad Lekarski, 2014)
• Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption (Frontiers in Pharmacology, 2012)
• Electronic cigarettes: The nicotyrine hypothesis (Medical Hypotheses, 2015)
• Nicotine-mecamylamine interactions (Clinical Pharmacology and Therapeutics, 2000)
• Tobacco Smoke Exposure Reduction Strategies-Do They Work? (Academic Pediatrics, 2021)
• Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial (World Psychiatry, 2021)
• Developmental Effects of Electronic Cigarette Use (Comprehensive Physiology, 2022)
• Tobacco-Derived and Tobacco-Free Nicotine cause differential inflammatory cell influx and MMP9 in mouse lung (Research Square, 2023)